Literature DB >> 20673545

Prevalence and treatment outcome in anxious versus nonanxious depression: results from the German Algorithm Project.

Katja Wiethoff1, Michael Bauer, Thomas C Baghai, Hans-Jürgen Möller, Robert Fisher, Dorothea Hollinde, Julia Kiermeir, Iris Hauth, Gerd Laux, Joachim Cordes, Peter Brieger, Klaus-Thomas Kronmüller, Joachim Zeiler, Mazda Adli.   

Abstract

OBJECTIVE: The objective of this study was to explore the prevalence of anxious depression in an inpatient population, to describe its clinical and sociodemographic correlates, and to compare treatment outcomes between patients with anxious and nonanxious depression. Furthermore, the efficacy of algorithm-guided treatment versus treatment as usual in patients with anxious versus nonanxious depression was evaluated.
METHOD: Data were collected on 429 inpatients with the diagnosis of a depressive episode (according to ICD-10) and a score of ≥ or = 15 on the 21-item Hamilton Depression Rating Scale (HDRS-21). The German Algorithm Project, phase 3 (GAP3), was conducted between 2000 and 2005 in 10 psychiatric departments throughout Germany. A baseline HDRS-21 anxiety/somatization factor score of ≥ or = 7 was considered indicative of anxious depression. Remission was defined as an HDRS-21 score or ≤ = 9. To evaluate the efficacy of algorithm-guided treatment, patients were randomly assigned into 3 groups: 2 different treatment algorithms or treatment as usual.
RESULTS: The prevalence of anxious depression was 49%. Patients with anxious depression were more likely than those with nonanxious depression to be older (mean ± SD = 45.3 ± 12.8 vs 42.9 ± 12.0 years, odds ratio [OR] = 1.02 [95% CI, 1.00-1.03], P = .046), retired (70% vs 30%, OR = 3.09 [95% CI, 1.70-5.62], P = .000), without school qualification (74% vs 26%, OR = 3.11 [95% CI, 1.09-8.83], P = .035), more severely depressed (mean ± SD HDRS-21 score = 20.1 ± 5.0 vs 18.5 ± 4.4, OR = 1.08 [95% CI, 1.03-1.12], P = .001), and more likely to have a longer duration of the current episode (mean ± SD = 20.9 ± 26.2 vs 13.7 ± 14.3 weeks, OR = 1.02 [95% CI, 1.01-1.03], P = .011). Patients with anxious depression were more likely to display a variety of melancholic features. In patients with anxious depression compared to those with nonanxious depression, remission was less likely to be achieved (48.6% vs 61.5%, OR = 0.63 [95% CI, 0.42-0.92], P = .018) and took longer to occur (mean ± SD = 44 ± 3.4 vs 30 ± 2.8 days, HR = 0.65 [95% CI, 0.50-0.85], P = .001). There was no significant interaction with the treatment mode with regard to remission (Wald = 0.20, P = .890).
CONCLUSIONS: Anxious depression is common in patients diagnosed with depression. The poorer treatment outcome in patients with anxious depression demonstrates the need to address the issue of specific treatment strategies for this subgroup. However, anxious depression has no moderating effect on the efficacy of algorithm-guided treatment. TRIAL REGISTRATION: http://www.germanctr.de/ Identifier: DRKS00000161. Copyright 2010 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20673545     DOI: 10.4088/JCP.09m05650blu

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  31 in total

1.  Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression.

Authors:  Boadie W Dunlop; Devon LoParo; Becky Kinkead; Tanja Mletzko-Crowe; Steven P Cole; Charles B Nemeroff; Helen S Mayberg; W Edward Craighead
Journal:  Am J Psychiatry       Date:  2019-02-15       Impact factor: 18.112

2.  Pharmacologic treatment of dimensional anxious depression: a review.

Authors:  Dawn F Ionescu; Mark J Niciu; Erica M Richards; Carlos A Zarate
Journal:  Prim Care Companion CNS Disord       Date:  2014-05-29

3.  Outcomes of acute phase cognitive therapy in outpatients with anxious versus nonanxious depression.

Authors:  Jasper A J Smits; Abu Minhajuddin; Michael E Thase; Robin B Jarrett
Journal:  Psychother Psychosom       Date:  2012-03-03       Impact factor: 17.659

4.  Subtypes of depression and their overlap in a naturalistic inpatient sample of major depressive disorder.

Authors:  Richard Musil; Florian Seemüller; Sebastian Meyer; Ilja Spellmann; Mazda Adli; Michael Bauer; Klaus-Thomas Kronmüller; Peter Brieger; Gerd Laux; Wolfram Bender; Isabella Heuser; Robert Fisher; Wolfgang Gaebel; Rebecca Schennach; Hans-Jürgen Möller; Michael Riedel
Journal:  Int J Methods Psychiatr Res       Date:  2017-06-14       Impact factor: 4.035

5.  Ziprasidone augmentation for anxious depression.

Authors:  Dawn F Ionescu; Richard C Shelton; Lee Baer; Kathryn H Meade; Michaela B Swee; Maurizio Fava; George I Papakostas
Journal:  Int Clin Psychopharmacol       Date:  2016-11       Impact factor: 1.659

6.  Anxious depression as a clinically relevant subtype of pediatric major depressive disorder.

Authors:  Isabelle Häberling; Noemi Baumgartner; Sophie Emery; Paola Keller; Michael Strumberger; Kristin Nalani; Klaus Schmeck; Suzanne Erb; Silke Bachmann; Lars Wöckel; Ulrich Müller-Knapp; Brigitte Contin-Waldvogel; Bruno Rhiner; Susanne Walitza; Gregor Berger
Journal:  J Neural Transm (Vienna)       Date:  2019-08-27       Impact factor: 3.575

Review 7.  Neurobiology of anxious depression: a review.

Authors:  Dawn F Ionescu; Mark J Niciu; Daniel C Mathews; Erica M Richards; Carlos A Zarate
Journal:  Depress Anxiety       Date:  2013-03-11       Impact factor: 6.505

8.  Blockade of NOP receptor modulates anxiety-related behaviors in mice exposed to inescapable stress.

Authors:  Aldemara I Silva; Victor A D Holanda; Joaquim G Azevedo Neto; Edilson D Silva Junior; Vanessa P Soares-Rachetti; Girolamo Calo; Chiara Ruzza; Elaine C Gavioli
Journal:  Psychopharmacology (Berl)       Date:  2020-02-24       Impact factor: 4.530

9.  Anxious-depression among Hispanic/Latinos from different backgrounds: results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL).

Authors:  Álvaro Camacho; Patricia Gonzalez; Christina Buelna; Kristen T Emory; Gregory A Talavera; Sheila F Castañeda; Rebeca A Espinoza; Annie G Howard; Krista M Perreira; Carmen R Isasi; Martha L Daviglus; Scott C Roesch
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2015-09-12       Impact factor: 4.328

Review 10.  Defining anxious depression: a review of the literature.

Authors:  Dawn F Ionescu; Mark J Niciu; Ioline D Henter; Carlos A Zarate
Journal:  CNS Spectr       Date:  2013-03-14       Impact factor: 3.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.